For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Protagonist Therapeutics Inc’s stock clocked out at $38.52, up 2.50% from its previous closing price of $37.58. In other words, the price has increased by $2.50 from its previous closing price. On the day, 0.54 million shares were traded. PTGX stock price reached its highest trading level at $38.62 during the session, while it also had its lowest trading level at $37.72.
Ratios:
To gain a deeper understanding of PTGX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.90 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.01. For the most recent quarter (mrq), Quick Ratio is recorded 10.70 and its Current Ratio is at 10.70. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on December 06, 2024, initiated with a Neutral rating and assigned the stock a target price of $47.
On December 06, 2024, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $62.
On November 05, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $58.Wedbush initiated its Outperform rating on November 05, 2024, with a $58 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 27 ’24 when MOLINA ARTURO MD sold 26,000 shares for $44.70 per share. The transaction valued at 1,162,280 led to the insider holds 46,444 shares of the business.
MOLINA ARTURO MD sold 5,529 shares of PTGX for $252,122 on Nov 26 ’24. The Chief Medical Officer now owns 46,444 shares after completing the transaction at $45.60 per share. On Nov 25 ’24, another insider, Gupta Suneel, who serves as the Chief Development Officer of the company, sold 103,437 shares for $46.04 each. As a result, the insider received 4,762,239 and left with 256,174 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTGX now has a Market Capitalization of 2295715072 and an Enterprise Value of 1837894656. As of this moment, Protagonist’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.45. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.12. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.09 while its Price-to-Book (P/B) ratio in mrq is 4.31. Its current Enterprise Value per Revenue stands at 5.676 whereas that against EBITDA is 12.247.
Stock Price History:
The Beta on a monthly basis for PTGX is 2.33, which has changed by 0.4392953 over the last 52 weeks, in comparison to a change of 0.208081 over the same period for the S&P500. Over the past 52 weeks, PTGX has reached a high of $48.89, while it has fallen to a 52-week low of $24.22. The 50-Day Moving Average of the stock is -3.12%, while the 200-Day Moving Average is calculated to be -0.05%.
Shares Statistics:
It appears that PTGX traded 693.46K shares on average per day over the past three months and 486470 shares per day over the past ten days. A total of 59.52M shares are outstanding, with a floating share count of 56.11M. Insiders hold about 5.86% of the company’s shares, while institutions hold 101.10% stake in the company. Shares short for PTGX as of 1736899200 were 3670399 with a Short Ratio of 5.29, compared to 1734048000 on 3608116. Therefore, it implies a Short% of Shares Outstanding of 3670399 and a Short% of Float of 6.239999999999999.
